Shareholder Alert: Robbins LLP Reminds Investors Covetrus, Inc. (CVET) Sued for Making Misleading Statements

SAN DIEGO & PORTLAND, Maine–(BUSINESS WIRE)–$CVET #ClassAction–Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Covetrus, Inc. (NASDAQ: CVET) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and August 12, 2019. Covetrus operates as an animal-health technology and services company.

If you suffered a loss as a result of Covetrus’ misconduct, click here.

Covetrus, Inc. (CVET) Accused of Misleading Shareholders

According to the complaint, on April 23, 2018, Henry Schein announced the spin-off and merger of the Animal Health Business of Henry Schein with Vets First Choice (“VFC”). Covetrus shares began trading on February 8, 2019. Throughout the class period and in the Offering Documents for the spin-merger, Henry Schein highlighted Covetrus’ strengths and touted Covetrus as a technology-enabled animal health business with a comprehensive service and technology platform and supply chain infrastructure. These benefits were reaffirmed later in Covetrus’ financial reports and the Company reassured that the integration was “on track” to hit financial targets. However, in reality, Covetrus’ strengths were overstated and the costs of the integration as well as the separation of Covetrus from Henry Schein had been much higher than represented. Then, on August 13, 2019, Covetrus shockingly reported a net loss of $0.09 per share rather than the expected increase of $0.17 per share and slashed its EBITDA guidance from estimates of $250 million to a realized $200 million. In its explanation, Covetrus confessed the undisclosed difficulties it was having in platform integration and separations costs from Henry Schein. Since this news, Covetrus’ stock has plummeted with a decline of $9.71, or 42%, per share and currently trades at around $13.50.

Covetrus, Inc. (CVET) Shareholders Have Legal Options

Contact us to learn more:

Leo Kandinov

(800) 350-6003

lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003

www.robbinsllp.com

Staff

Recent Posts

Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext…

21 mins ago

Charting the Future of Nutrition: Mission Hill Foods Expands Research and Strengthens Market Presence in North America

Discover Mission Hill Foods' investment in advanced research, development, and sustainable practices for consumer health.CALIFORNIA…

3 hours ago

Leading the Future of Nutrition: Mission Hill Foods’ Innovations in Scientific Research and Sustainability

Exploring Mission Hill Foods' Pursuit of Excellence in Nutrition and Environmental ResponsibilityCALIFORNIA CITY, CA /…

3 hours ago

CardioComm Solutions Completes Debt Settlement

Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…

7 hours ago

ProAssurance to Announce Second Quarter 2024 Results on Thursday, August 8, 2024

Investor call to be held at 10:30 a.m. ET on Friday, August 9BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance…

9 hours ago

NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

9 hours ago